Literature DB >> 30282666

Efficacy of JAK1/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency.

Coralie Briand1, Marie-Louise Frémond1,2,3, Didier Bessis4, Aurélia Carbasse5, Gillian I Rice6, Vincent Bondet7,8, Darragh Duffy7,8,9, Lucienne Chatenoud2,10,11, Stéphane Blanche1,2, Yanick J Crow2,3,12, Bénédicte Neven13,2,14.   

Abstract

Entities:  

Keywords:  inflammation; rehabilitation; treatment

Mesh：

Substances：

Year:  2018        PMID： 30282666     DOI： 10.1136/annrheumdis-2018-214037

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  17 in total

Review 1.  Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach.

Authors:  Peter A Nigrovic; Pui Y Lee; Hal M Hoffman
Journal:  J Allergy Clin Immunol       Date:  2020-11       Impact factor: 10.793

Review 2.  Moving towards a systems-based classification of innate immune-mediated diseases.

Authors:  Sinisa Savic; Emily A Caseley; Michael F McDermott
Journal:  Nat Rev Rheumatol       Date:  2020-02-27       Impact factor: 20.543

3.  DNA damage contributes to neurotoxic inflammation in Aicardi-Goutières syndrome astrocytes.

Authors:  Marco Luciani; Francesca Gatto; Monah Abou Alezz; Anna Maria Sole Giordano; Chiara Beghè; Lucrezia Della Volpe; Alessandro Migliara; Sara Valsoni; Marco Genua; Monika Dzieciatkowska; Giacomo Frati; Julie Tahraoui-Bories; Silvia Clara Giliani; Simona Orcesi; Elisa Fazzi; Renato Ostuni; Angelo D'Alessandro; Raffaella Di Micco; Ivan Merelli; Angelo Lombardo; Martin A M Reijns; Natalia Gromak; Angela Gritti; Anna Kajaste-Rudnitski
Journal:  J Exp Med       Date:  2022-03-09       Impact factor: 14.307

4.  Janus Kinase Inhibition in the Aicardi-Goutières Syndrome.

Authors:  Adeline Vanderver; Laura Adang; Francesco Gavazzi; Katherine McDonald; Guy Helman; David B Frank; Nicole Jaffe; Sabrina W Yum; Abigail Collins; Stephanie R Keller; Pierre Lebon; Jean-François Meritet; Jullie Rhee; Asako Takanohashi; Thais Armangue; Nicole Ulrick; Omar Sherbini; Jamie Koh; Kyle Peer; Constance Besnier; Carly Scher; Katherine Boyle; Holly Dubbs; Julia Kramer-Golinkoff; Amy Pizzino; Sarah Woidill; Justine Shults
Journal:  N Engl J Med       Date:  2020-09-03       Impact factor: 91.245

5.  Mutations in COPA lead to abnormal trafficking of STING to the Golgi and interferon signaling.

Authors:  Alice Lepelley; Maria José Martin-Niclós; Melvin Le Bihan; Joseph A Marsh; Carolina Uggenti; Gillian I Rice; Vincent Bondet; Darragh Duffy; Jonny Hertzog; Jan Rehwinkel; Serge Amselem; Siham Boulisfane-El Khalifi; Mary Brennan; Edwin Carter; Lucienne Chatenoud; Stéphanie Chhun; Aurore Coulomb l'Hermine; Marine Depp; Marie Legendre; Karen J Mackenzie; Jonathan Marey; Catherine McDougall; Kathryn J McKenzie; Thierry Jo Molina; Bénédicte Neven; Luis Seabra; Caroline Thumerelle; Marie Wislez; Nadia Nathan; Nicolas Manel; Yanick J Crow; Marie-Louise Frémond
Journal:  J Exp Med       Date:  2020-11-02       Impact factor: 14.307

Review 6.  The type I interferonopathies: 10 years on.

Authors:  Yanick J Crow; Daniel B Stetson
Journal:  Nat Rev Immunol       Date:  2021-10-20       Impact factor: 108.555

Review 7.  Interferon target-gene expression and epigenomic signatures in health and disease.

Authors:  Franck J Barrat; Mary K Crow; Lionel B Ivashkiv
Journal:  Nat Immunol       Date:  2019-11-19       Impact factor: 25.606

Review 8.  Immune Dysfunction in Mendelian Disorders of POLA1 Deficiency.

Authors:  Petro Starokadomskyy; Andrea Escala Perez-Reyes; Ezra Burstein
Journal:  J Clin Immunol       Date:  2021-01-03       Impact factor: 8.542

9.  Development and Validation of a Targeted Next-Generation Sequencing Gene Panel for Children With Neuroinflammation.

Authors:  Dara McCreary; Ebun Omoyinmi; Ying Hong; Ciara Mulhern; Charalampia Papadopoulou; Marina Casimir; Yael Hacohen; Rodney Nyanhete; Helena Ahlfors; Thomas Cullup; Ming Lim; Kimberly Gilmour; Kshitij Mankad; Evangeline Wassmer; Stefan Berg; Cheryl Hemingway; Paul Brogan; Despina Eleftheriou
Journal:  JAMA Netw Open       Date:  2019-10-02

10.  Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions.

Authors:  Tanja Fetter; Paul Smith; Tugce Guel; Christine Braegelmann; Thomas Bieber; Joerg Wenzel
Journal:  Front Immunol       Date:  2020-03-03       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.